The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

Retatrutide

Off-label · Grade C

Goals
weight-loss, gut, mitochondria
Evidence
5 RCT / 0 animal / 0 in vitro
Routes
injectable-sc
WADA
S0
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
The peptide is modified with a C18 fatty acid chain via a linker to albumin binding, extending its plasma half-life to approximately 6-7 days — enabling the once-weekly subcutan…
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Mazdutide

Research chemical · Grade C

Goals
weight-loss, gut, mitochondria
Evidence
5 RCT / 1 animal / 0 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Survodutide

Research chemical · Grade C

Goals
weight-loss, gut, mitochondria
Evidence
3 RCT / 1 animal / 0 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Cagrilintide

Research chemical · Grade C

Goals
weight-loss, gut
Evidence
3 RCT / 1 animal / 0 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →